智通财经APP获悉，堃博医疗-B(02216)盘中涨超12%，截至发稿，涨11.17%，报2.29港元，成交额2733.99万港元。
消息面上，堃博医疗今年4月公告，旗下BroncAblate智衡一次性使用肺部射频消融导管获批上市。公司6月再发公告，核心产品BroncAblate智衡主机正式获得中国国家药品监督管理局(NMPA)批准上市。至此，BroncAblate智衡肺部射频消融系统这款全球首款经自然腔道(支气管)射频消融肺癌治疗器械正式进入商业化进程。
华泰证券此前发布研报称，新品研发有序推进，持续拓宽产品矩阵。RF-II用于肺癌治疗，其上市前临床试验结果已于24年8月发布，公司预计其将于25年在国内上市并启动商业化。TLD用于COPD治疗，截至24年底已在超20家医院完成患者入组近百例，公司预计其将于26年完成全部随访。经自然腔道柔性手术机器人目前处于前期研究阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.